Myeloproliferative Neoplasms Clinical Trial
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).
Have an Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 or 2
Have the following hematologic laboratory values: Leukocytes greater than or equal to (>=) 1.5*10^9 per liter, Neutrophils >=1.0*10^9 per liter, Platelets >=20*10^9 per liter, Hemoglobin greater than (>) 7 gram per deciliter (g/dL)
Have the following chemistry laboratory values: Alanine aminotransferase (ALT): less than or equal to (<=) 3*upper limit of normal (ULN), aspartate aminotransferase (AST): <=3*ULN, total bilirubin: <=1.5*ULN, and glomerular filtration rate >=40 milliliter per minute (mL/min)
A female participant of childbearing potential must agree to all the following during the study and for 6 months after the last dose of study treatment: use a barrier method of contraception, use a highly effective preferably user-independent method of contraception, not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction, not plan to become pregnant, not to breast-feed
A male participant must agree to all the following during the study and for 90 days after the last dose of study treatment: wear a condom when engaging in any activity that allows for passage of ejaculate to another person, not to father a child, not to donate sperm or freeze for future use for the purpose of reproduction
History of any significant medical condition per investigators judgment (example: severe asthma/chronic obstructive pulmonary disease (COPD), poorly regulated heart condition, insulin dependent diabetes mellitus)
Serious known clinically relevant allergies or earlier anaphylactic reactions
Currently pregnant or breastfeeding
Prior treatment with any Janus kinase 2 (JAK2) inhibitor
Known sensitivity or contraindications to the use of Ipilimumab per local prescribing information
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Birmingham Alabama, 35233, United States
Phoenix Arizona, 85054, United States
Duarte California, 91010, United States
Tampa Florida, 33612, United States
Rochester Minnesota, 55905, United States
Cleveland Ohio, 44195, United States
Philadelphia Pennsylvania, 19104, United States
Nashville Tennessee, 37232, United States
Houston Texas, 77030, United States
Toronto Ontario, M5G 1, Canada
Paris , 75010, France
Pamplona , 31008, Spain
Salamanca , 37007, Spain
Valencia , 46010, Spain
London , SE1 9, United Kingdom
Manchester , M20 4, United Kingdom
Oxford , OX3 7, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.